

2022 Annual General Meeting Results

Perth, Australia; 24 November 2022. NeuroScientific Biopharmaceuticals Ltd ASX: NSB ("NeuroScientific" or "the Company") wishes to provide the results of the Annual General Meeting held on 24 November 2022, which are authorised for release by the NeuroScientific Biopharmaceuticals Limited Company Secretary.

Yours faithfully



Abby Macnish Niven
Company Secretary

END

Announcement authorised by the Company Secretary of NeuroScientific Biopharmaceuticals.

For more information please contact:

Paul Rennie
Interim CEO & Chairman
NeuroScientific Biopharmaceuticals
ir@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatestorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.

Disclosure of Proxy Votes

NeuroScientific Biopharmaceuticals Limited

Annual General Meeting

Thursday, 24 November 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	12,204,183	8,809,026 72.18%	534,261 4.38%	327,809	2,860,896 23.44%	11,569,922 95.54%	540,261 4.46%	392,666
2 Re-election of Director – Anton Uvarov	P	12,834,296	9,117,103 71.04%	859,897 6.70%	97,696	2,857,296 22.26%	9,017,103 70.78%	3,723,193 29.22%	162,553
3 Approval of 7.1A Mandate	P	12,928,992	9,457,168 73.15%	604,528 4.68%	3,000	2,867,296 22.18%	12,324,464 96.02%	510,528 3.98%	67,857
4 Increase in total Aggregate Remuneration for Non-Executive Directors	P	12,631,992	8,472,255 67.07%	1,296,841 10.27%	300,000	2,862,896 22.66%	11,335,151 89.94%	1,267,698 10.06%	300,000

